Subjective Experience Following Psilocybin

Exclusion Criteria11

• Any notable abnormality on electrocardiogram or routine medical blood or urinalysis laboratory tests
• Current psychiatric diagnoses, such as: major depressive disorder, generalized anxiety disorder, panic disorder, social anxiety disorder, obsessive compulsive disorder, moderate to severe substance use disorders, eating disorders, personality disorders, post-traumatic stress disorder
• Lifetime or current psychiatric diagnoses of: psychosis, schizophrenia, bipolar disorder
• Family history: a first- or second degree relative with a history of schizophrenia or other psychotic disorders, bipolar I or II
• Medication: Any medication with the potential to interact with the investigational medicinal products, especially those with serotonergic mechanisms of actions like SSRIs, SNRIs or MAO-Inhibitors as well as other antipsychotics
• Currently pregnancy or nursing, trying to become pregnant, or unwilling to use acceptable method of contraception during the study
• Current or recent (within 12 weeks) participation in a clinical trial involving medication administration
• Cognitive impairment (Folsetin Mini Mental State Exam score < 24)
• A disorder that may interfere with drug absorption, distribution, metabolism, or excretion (including gastrointestinal surgery).
• Suffered a traumatic brain injury with one of the following symptoms Loss of consciousness >30min Alteration of consciousness/mental state >24h Post-traumatic amnesia >1 day Glasgow Coma Scale (best available score in first 24 hours) <13
• Any other circumstances that, in the opinion of the investigators, compromises participant safety